<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Short-term management goals for Gaucher disease type 1, ERT/SRT related&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Short-term management goals for Gaucher disease type 1, ERT/SRT related<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Short-term management goals for Gaucher disease type 1, ERT/SRT related<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup width="75%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Category</td> <td class="subtitle1">Management goals</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Anemia-related symptoms</td> <td>Eliminate blood transfusion dependency</td> </tr> <tr class="divider_bottom"> <td>Increase hemoglobin levels within 12 to 24 months to &gt;11.0 g/dL for females and children and &gt;12.0 g/dL for males</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Bleeding tendency</td> <td>Increase platelet counts during the first year of treatment sufficiently to prevent surgical, obstetrical, and spontaneous bleeding</td> </tr> <tr> <td>In patients with splenectomy – Normalization of platelet count by one year of treatment</td> </tr> <tr class="divider_bottom"> <td>In patients with an intact spleen – Achieve platelet count of ≥100,000/mm<sup>3</sup> by 3 years of treatment</td> </tr> <tr> <td class="divider_bottom" rowspan="5">Mobility</td> <td>Lessen bone pain that is not related to irreversible bone disease within 1 to 2 years</td> </tr> <tr> <td>Decrease bone marrow involvement, as measured by a locally used scoring system (eg, BMB score or DGS) in patients without severe irreversible bone disease at baseline</td> </tr> <tr> <td>Increase BMD by 2 years in adults for patients with a T-score below –2.5 at baseline</td> </tr> <tr> <td>Attain normal or ideal peak skeletal mass in children</td> </tr> <tr class="divider_bottom"> <td>Normalize growth such that the height of the patient is in line with target height, based upon population standards and parental height, within 2 years of treatment</td> </tr> <tr> <td class="divider_bottom" rowspan="5">Visceral complications</td> <td>Avoid splenectomy (may be necessary during life-threatening hemorrhagic events)</td> </tr> <tr> <td>Alleviate symptoms due to splenomegaly: abdominal distension, early satiety, new splenic infarction</td> </tr> <tr> <td>Eliminate hypersplenism</td> </tr> <tr> <td>Reduce spleen volume to &lt;2 to 8 times normal (or in absence of volume measurement tools reduce spleen size) by year 1 to 2, depending on baseline spleen volume</td> </tr> <tr class="divider_bottom"> <td>Reduce the liver volume to 1 to 1.5 times normal (or in absence of volume measurement tools aim for normal liver size) by year 1 to 2, depending on baseline liver volume</td> </tr> <tr> <td rowspan="3">General well-being</td> <td>Improve scores from baseline of a validated quality-of-life instrument within 2 to 3 years or less depending on disease burden</td> </tr> <tr> <td>Reduce fatigue (not anemia related) as measured by a validated fatigue scoring system</td> </tr> <tr> <td>Improve or restore physical function for carrying out normal daily activities and fulfilling functional roles</td> </tr> </tbody></table></div><div class="graphic_footnotes">ERT: enzyme replacement therapy; SRT: substrate reduction therapy; BMB: Bone Marrow Burden; DGS: Düsseldorf Gaucher Score; BMD: bone mineral density.</div><div class="graphic_reference">Reference:
<ol>
<li>Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4.</li>
</ol>
<p class="extra_spacing_top">From: Biegstraaten M, Cox TM, Belmatoug N, et al. Management goals for type 1 Gaucher disease: An expert consensus document for the European working group on Gaucher disease. Blood Cells Mol Dis 2018; 68:203. Copyright © 2018 Elsevier, Inc. Available at: <a href="https://www.sciencedirect.com/science/article/pii/S1079979616301917?via%3Dihub" target="_blank">https://www.sciencedirect.com/science/article/pii/S1079979616301917?via%3Dihub</a> (Accessed November 20, 2017). Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License</a>.</p></div><div id="graphicVersion">Graphic 115668 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
